We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

64 hedge funds and large institutions have $67.4M invested in Matinas BioPharma in 2019 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

386% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 7

306% more capital invested

Capital invested by funds: $16.6M → $67.4M (+$50.8M)

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

73% more funds holding

Funds holding: 37 → 64 (+27)

0.04% more ownership

Funds ownership: 0.32% → 0.37% (+0.04%)

Holders
64
Holders Change
+27
Holders Change %
+72.97%
% of All Funds
1.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
34
Increased
11
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.61M
2
BBA
Baker Bros. Advisors
New York
+$750K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$678K
4
ECM
ExodusPoint Capital Management
New York
+$549K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$356K

Top Sellers

Rank Fund Capital Flow
1
GPCM
Granite Point Capital Management
Massachusetts
-$946K
2
Millennium Management
Millennium Management
New York
-$341K
3
Victory Capital Management
Victory Capital Management
Texas
-$337K
4
TI
Telemetry Investments
New York
-$272K
5
LTFS
Ladenburg Thalmann Financial Services
Florida
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
FC
51
Fore Capital
New York
$23K – – –
BFM
52
Boothbay Fund Management
New York
$23K +$11.6K +200 New
Citigroup
53
Citigroup
New York
$23K +$11.6K +200 New
FAIM
54
Financial Advocates Investment Management
Washington
$23K +$11.6K +200 New
Franklin Resources
55
Franklin Resources
California
$23K +$11.6K +200 New
AG
56
Advisor Group
Arizona
$9K – – –
UBS Group
57
UBS Group
Switzerland
$8K +$4.17K +72 New
HFM
58
Hartford Financial Management
Connecticut
$6K – – –
CAL
59
Capital Analysts LLC
Pennsylvania
$3K +$1.45K +25 New
EWM
60
Endurance Wealth Management
Rhode Island
$2K +$1.45K +25 New
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
$57 – – –
WCA
62
Windsor Creek Advisors
Vermont
$33 +$17K +294 New
GPCM
63
Granite Point Capital Management
Massachusetts
– -$946K -30,000 Closed
TI
64
Telemetry Investments
New York
– -$272K -8,631 Closed
LTFS
65
Ladenburg Thalmann Financial Services
Florida
– -$16K -500 Closed
RJA
66
Raymond James & Associates
Florida
– -$11K -340 Closed
Two Sigma Investments
67
Two Sigma Investments
New York
– -$7K -225 Closed
GIA
68
Gladstone Institutional Advisory
Florida
– -$6K -200 Closed
Fidelity Investments
69
Fidelity Investments
Massachusetts
– -$1K -24 Closed
TWA
70
TCI Wealth Advisors
Arizona
– +$116 +2 New
1 2
3

MTNB Hedge Fund Activity: Q4 2019 in Review

64 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q4 2019, worth a combined $67.4M — up 306% from $16.6M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new MTNB positions and 7 closed out — a net gain of 27 holders — while 11 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $1.61M. The largest seller was Granite Point Capital Management, exiting entirely with an estimated $946K sold.

  • 64 institutional investors held Matinas BioPharma (MTNB) as of Q4 2019, up from 37 in Q3 2019.
  • Funds reported $67.4M of Matinas BioPharma stock for Q4 2019, up 306% quarter-over-quarter.
  • 34 funds opened new Matinas BioPharma positions in Q4 2019 and 7 closed out, a net change of +27 holders.
  • The largest Matinas BioPharma buyer in Q4 2019 was BlackRock, an estimated $1.61M added.
  • The largest Matinas BioPharma seller in Q4 2019 was Granite Point Capital Management, an estimated $946K sold.

Based on aggregated 13F filings for Q4 2019.